Lupin Ltd.
Price
Daily candles · NSEWhat the numbers say
- Good return on equity: 3-year ROE 20.9%.
- Comfortable leverage: debt-to-equity of 0.26.
- Sales compounded at 18.9% over 3 years.
- Profits convert to cash well (CFO/OP 0.75).
- Trades below its industry P/E (16.5 vs 25.9).
Generated automatically from reported financials. These are observations, not a recommendation to buy or sell.
- Lupin gets USFDA’s approval for Phytonadione Injectable Emulsion
Phytonadione Injectable is indicated for the treatment and prophylaxis of hypoprothrombinemia (low blood clotting) and vitamin K-deficiency
- Lupin launches world’s first triple combination drug ‘Formoflo-G MDI’ for COPD in India
The product is available as a twice-daily, single-strength fixed dose, bringing hope to more than 55 million people living with COPD in India
- Lupin gets USFDA’s tentative nod for Novel Apixaban Oral Suspension
Upon final approval, the product will be manufactured at the company’s Somerset, New Jersey facility
- Lupin gets USFDA’s final nod for Pitolisant Tablets
The USFDA has approved the company’s Pitolisant Tablets, 4.45 mg and 17.8 mg, as bioequivalent to Wakix for the indications in the approved labeling
- Lupin gets USFDA’s nod for Sodium Zirconium Cyclosilicate for Oral Suspension in US
Sodium Zirconium Cyclosilicate for Oral Suspension (RLD Lokelma) had estimated annual sales of $568 million in the U.S
- Lupin reports 16% rise in Q1 consolidated net profit
Consolidated total income of the company increased by 32.45% to Rs 8,407.21 crore for Q1FY27
- Lupin launches Sugammadex Injection in United States
The company’s Sugammadex Injection is the bioequivalent to Bridion Injection of Merck, Sharp & Dohme LLC
- Lupin gets EIR from USFDA for Somerset facility
The inspection was conducted from April 13, 2026, to April 17, 2026
Company announcements as filed with the exchanges. Reproduced for information — not a view or a recommendation.
| Profit & Loss · ₹ crore | FY26 | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|---|
| Net Sales | 27,958 | 22,708 | 20,011 | 16,642 | 16,405 |
| Other income | 1,081 | 202 | 142 | 151 | 214 |
| Total Income | 29,039 | 22,910 | 20,152 | 16,793 | 16,619 |
| Expenditure | 19,799 | 17,430 | 16,222 | 14,921 | 16,190 |
| Operating Profit | 9,240 | 5,479 | 3,931 | 1,871 | 429 |
| Interest | 434 | 295 | 312 | 274 | 143 |
| Depreciation | 1,376 | 1,169 | 1,197 | 881 | 1,659 |
| Profit before tax | 6,873 | 4,015 | 2,422 | 716 | -1,372 |
| Tax | 1,517 | 709 | 487 | 269 | 137 |
| Net Profit | 5,355 | 3,306 | 1,936 | 448 | -1,509 |
| EPS (₹) | 116.75 | 71.95 | 42.05 | 9.46 | -33.65 |
| Net margin % | 19.2 | 14.6 | 9.7 | 2.7 | -9.2 |
Consolidated figures, as filed with the exchanges. Newest year first.
| Balance Sheet · ₹ crore | FY26 | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|---|
| Equity capital | 91 | 91 | 91 | 91 | 91 |
| Reserves | 22,293 | 17,028 | 14,085 | 12,225 | 11,901 |
| Net worth | 22,384 | 17,120 | 14,176 | 12,316 | 11,992 |
| Total sources | 25,495 | 20,017 | 15,250 | 13,461 | 13,304 |
| Net block | 10,994 | 9,719 | 8,878 | 8,355 | 7,382 |
| Capital work in progress | 1,016 | 517 | 773 | 1,238 | 1,146 |
| Investments | 5,340 | 2,670 | 1,443 | 1,196 | 1,488 |
| Inventory | 6,083 | 5,476 | 4,954 | 4,492 | 4,631 |
| Debtors | 6,604 | 5,497 | 4,692 | 4,481 | 4,262 |
| Cash & bank | 5,653 | 3,142 | 1,203 | 1,293 | 1,098 |
| Book value (₹) | 489.59 | 374.93 | 311.08 | 270.67 | 263.84 |
Consolidated figures, as filed with the exchanges. Newest year first.
| Cash Flow · ₹ crore | FY26 | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|---|
| From operations | 7,335 | 3,000 | 3,648 | 1,897 | 367 |
| From investing | -3,865 | -4,172 | -1,712 | -1,287 | 1,292 |
| From financing | -846 | 1,732 | -2,184 | -337 | -1,572 |
| Net change in cash | 2,624 | 560 | -248 | 273 | 87 |
| Free cash flow | 3,470 | -1,172 | 1,936 | 610 | 1,660 |
| Closing cash | 4,168 | 1,544 | 984 | 1,265 | 1,013 |
Consolidated figures, as filed with the exchanges. Newest year first.
| Ratios | FY26 | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|---|
| ROCE % | 28.9 | 22.0 | 16.2 | 6.1 | -7.1 |
| ROE % | 27.1 | 21.1 | 14.6 | 3.7 | -11.8 |
| PAT margin % | 12.4 | 8.9 | 6.1 | 1.6 | -5.1 |
| EBIT margin % | 16.9 | 11.6 | 8.6 | 3.5 | -4.1 |
| Debt / equity | 0.26 | 0.30 | 0.19 | 0.34 | 0.32 |
| Current ratio | 1.90 | 1.87 | 1.58 | 1.34 | 1.51 |
| Interest cover | 16.82 | 14.62 | 8.77 | 3.61 | -8.61 |
| Sales growth % | 23.1 | 13.5 | 20.2 | 1.4 | 8.2 |
| Dividend per share (₹) | 18.00 | 12.00 | 8.00 | 4.00 | 4.00 |
| Payout % | 15.4 | 16.7 | 19.0 | 42.3 | -11.9 |
Consolidated figures, as filed with the exchanges. Newest year first.
Frequently asked
Lupin Ltd. (LUPIN) last traded at ₹1,922.00 on the NSE, down +2.14% on the session. Prices on this page are indicative and for information only.
Lupin Ltd. has traded between ₹1,896.10 and ₹2,529.50 over the last 52 weeks on the NSE.
Lupin Ltd. has a market capitalisation of about ₹87,874 crore.
Lupin Ltd. trades at a P/E of 16.5, against an industry P/E of 25.9.
Open a trading and Demat account with Labdhi — it is fully digital with paperless KYC — then place a buy order for LUPIN from the Labdhi app or web platform.
Yes. You can invest in equities in a staggered manner through Labdhi. Speak to your Labdhi adviser about a plan suited to your goals and risk profile.
Who is actually trading it
Delivery against churn, the deals big enough to be reported, what the insiders did, and the benchmarks that hold Lupin Ltd..
Loading trading activity…
Exchange filings and end-of-day data, not a live feed. Bulk, block and insider records are published by the exchanges when a threshold is crossed, so they show reportable activity only. For information, not a recommendation to deal, and not a view on any person named above.
Disclosures. Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI, membership of BASL (in case of IAs) and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.
Prices and data on this page are indicative and for information only. Nothing here is investment advice or a recommendation to buy or sell any security. Investors should consider their own objectives, financial situation and risk profile, and may wish to seek independent advice, before investing.
Figures are as reported by the company; consolidated where available. Errors and omissions excepted.
L. F. C. Securities Pvt. Ltd. · Member BSE, NSE, MCX · SEBI Stock Broker INZ000170736 · CDSL IN-DP-281-2016 · AMFI ARN-78991 · Investment Adviser (Non-Individual) INA000011617 · Compliance Officer: Mr. Santosh Patil · santoshp@labdhi.in · 022-35006933 · Investor Grievances: investorgreve@labdhi.in